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Prediction Score for Anticoagulation Control Quality Among Older
Adults
Kueiyu Joshua Lin, MD, ScD, MPH; Daniel E. Singer, MD; Robert J. Glynn, PhD, ScD; Suzanne Blackley, MA; Li Zhou, MD, PhD;
Jun Liu, MD; Gina Dube, PharmD, CACP, RPh; Lynn B. Oertel, MS, ANP-BC, CACP; Sebastian Schneeweiss, MD, ScD
Background-—Time in the therapeutic range (TTR) is associated with the effectiveness and safety of vitamin K antagonist (VKA)
therapy. To optimize prescribing of VKA, we aimed to develop and validate a prediction model for TTR in older adults taking VKA for
nonvalvular atrial ﬁbrillation and venous thromboembolism.
Methods and Results-—The study cohort comprised patients aged ≥65 years who were taking VKA for atrial ﬁbrillation or
venous thromboembolism and who were identiﬁed in the 2 US electronic health record databases linked with Medicare claims
data from 2007 through 2014. With the predictors identiﬁed from a systematic review and clinical knowledge, we built a
prediction model for TTR, using one electronic health record system as the training set and the other as the validation set.
We compared the performance of the new models to that of a published prediction score for TTR, SAMe-TT2R2. Based on
1663 patients in the training set and 1181 in the validation set, our optimized score included 42 variables and the simpliﬁed
model included 7 variables, abbreviated as PROSPER (Pneumonia, Renal dysfunction, Oozing blood [prior bleeding], Staying in
hospital ≥7 days, Pain medication use, no Enhanced [structured] anticoagulation services, Rx for antibiotics). The PROSPER
score outperformed SAMe-TT2R2 when predicting both TTR ≥70% (area under the receiver operating characteristic curve 0.67
versus 0.55) and the thromboembolic and bleeding outcomes (area under the receiver operating characteristic curve 0.62
versus 0.52).
Conclusions-—Our geriatric TTR score can be used as a clinical decision aid to select appropriate candidates to receive VKA
therapy and as a research tool to address confounding and treatment effect heterogeneity by anticoagulation quality. ( J Am Heart
Assoc. 2017;6:e006814. DOI: 10.1161/JAHA.117.006814.)
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V itamin K antagonist (VKA; eg, warfarin) therapy is aneffective anticoagulation option for stroke prevention in
patients with nonvalvular atrial ﬁbrillation (AF) and for
treatment and secondary prevention of venous thromboem-
bolism (VTE; including deep vein thrombosis and pulmonary
embolism).1–3 The safety and effectiveness of VKAs, however,
depends on regular international normalized ratio (INR)
monitoring and anticoagulation control quality, often
measured by the time in therapeutic range (TTR), for which
INR 2.0 to 3.0 is the standard therapeutic range for AF and
VTE.4–6 Patients on VKA with poor anticoagulation quality (ie,
low TTR) have been shown to have a higher risk of
thromboembolic and bleeding complications and thus a worse
risk–beneﬁt ratio.4,7,8
Although clinical trials have shown that direct-acting oral
anticoagulants (DOACs) are therapeutically advantageous over
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SYSTEMATIC REVIEW AND META-ANALYSIS
or at least noninferior to VKAs,9–11 clinical equipoise still exists
when patients are likely to have good anticoagulation control
based on pretreatment characteristics.7,12 This choice is
particularly difﬁcult to make in older adults because DOACs
have been associated with a higher risk of major gastrointesti-
nal bleeding than VKAs in the older population.13–15 Moreover,
chronic kidney disease is highly prevalent in older adults,16
which makes lack of routine monitoring tests for DOACs a
challenge rather than an advantage because some DOACs are
substantially renally excreted (eg, 80% for dabigatran). Conse-
quently, it is critical to understand how patient characteristics
are associated with anticoagulation quality so we can identify
the ideal candidates for VKA therapy.
In the existing literature, there is only 1 published
prediction score for anticoagulation quality: the SAMe-TT2R2
score.17 It did not consider some clinically important predic-
tors for TTR (eg, polypharmacy, hospitalizations, antibiotic
use)18–22 and was found to have suboptimal performance in
external validation populations (area under receiver operating
characteristic curve [AUC] for relevant clinical end points
<0.6).23–25 In addition, although the majority of oral antico-
agulant users are older adults,3,18 SAMe-TT2R2 was developed
with 52.7% of the population aged <70 years. Because
comorbidity proﬁles vary substantially by age, the generaliz-
ability and applicability of SAMe-TT2R2 in the older population
is unclear.
We aimed to develop and validate a new prediction model
for TTR, particularly in patients aged ≥65 years taking VKA for
nonvalvular AF or VTE. Because prior studies found that the
TTR predictors identiﬁed in AF patients were similar to those
in VTE patients,18 for clinical simplicity we developed 1 score
for both indications but validated the performance in patients
with nonvalvular AF and VTE separately.
Methods
Data Source
We linked electronic health record (EHR) data from 2 large US
academic provider networks with Medicare claims data. The
ﬁrst network consists of 1 tertiary hospital, 2 community
hospitals, 17 primary care centers, and 1 anticoagulation
clinic that manages VKA-related care for all patients within the
network. The second network includes 1 tertiary hospital, 1
community hospital, 16 primary care centers, and an
anticoagulation clinic. Patients in network 1 were used as
the training set for the prediction model derivation, and those
in network 2 were used as the validation set. The EHR
database contains information on patient demographics,
diagnosis and procedure codes, medications, lifestyle factors,
laboratory data, and various clinical notes. Both inpatient and
outpatient EHR data were used in this study. The Medicare
claims data contain information on demographics, inpatient
and outpatient diagnosis and procedure codes, and dispensed
medications.26 This study was approved by Partners Health-
Care Institutional Review Board (IRB).
Study Population
In the linked Medicare claims–EHR data, we identiﬁed all
patients aged ≥65 years with nonvalvular AF or VTE
initiating a VKA from January 1, 2007, to December 31,
2014, with no use of any oral anticoagulants (VKAs or
DOACs) in the prior 90 days (new user design27). The VKA
initiation date was the index (cohort entry) date. The study
cohort was required to have at least 180 days of contin-
uous enrollment in Medicare inpatient, outpatient, and
prescription beneﬁts with at least 1 EHR encounter with
date of service after January 1, 2007, and before the index
date. To ensure our ability to assess the primary outcome
reliably, patients were required to have at least 5 INR
values recorded in the system. To assess whether this
requirement would select an unrepresentative cohort, we
compared the distributions of the combined comorbidity
score28 in those with versus without at least 5 INRs. We
computed standardized differences between proportions of
each combined comorbidity score category in those with
versus without 5 INRs. A standardized difference of <0.1
was used to indicate an acceptable discrepancy.29
Outcome Deﬁnition of the Anticoagulation
Control
We calculated TTR using Rosendaal’s method,30 which
assigns an INR value to each day by linear interpolation of
successive observed INR values with gaps <56 days. After
interpolation, we computed the proportions of time that fell
Clinical Perspective
What Is New?
• In patients aged ≥65 years, our prediction model for
anticoagulation control quality outperformed the published
score, SAMe-TT2R2.
• Time in the therapeutic range was ≥70% (area under
receiver operating characteristic curve 0.71 versus 0.57, a
signiﬁcant difference.).
What Are the Clinical Implications?
• Our prediction score for anticoagulation quality can help
clinicians select the appropriate older adult candidates to
receive vitamin K antagonist therapy and can provide
researchers with a tool to adjust for confounding and to
investigate treatment effect heterogeneity due to predicted
anticoagulation quality.
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within the therapeutic range (INR 2.0–3.0). We ascertained
TTR starting the 29th day after the index date until the
earliest of the following: 12 months after the index date,
lack of INRs with a gap ≤56 days, death, discontinuation of
VKA, or study end (December 31, 2014). We did not
assess TTR for the ﬁrst month because variability of INR
values in the ﬁrst month generally reﬂects expected
ﬂuctuations in INRs during the titration phase of VKA
therapy. VKA discontinuation was deﬁned based on an
algorithm validated in a prior study in which high
agreement with actual VKA use was demonstrated by
chart review (j=0.84).31
Candidate Predictors and Building of the TTR
Prediction Model
We conducted a systematic review to identify original articles
reporting predictors of anticoagulation control quality
(assessed by TTR or INR variability) in users of VKAs, after
multivariate adjustment. Figure 1 summarizes the search
terms and the selection process. The signiﬁcant predictors
reported by the selected articles, along with variables deemed
clinically important to predict anticoagulation quality, were
used as the candidate predictors to build our prediction
model. Based on these variables, we built a model predicting
continuous TTR by Lasso regression with 5-fold cross-
validation, using the data in the training set.32 We referred
to the predicted TTR derived from this model as the geriatric
TTR score. To build a simpliﬁed model for clinical use, we
excluded biophysiologic variables requiring additional testing
and used Lasso regression with a Bayesian information
criterion, which tends to generate a more parsimonious model
than do other criteria.33 The points of the scoring system
were the nearest integer proportional to the unstandardized
coefﬁcient in this simpliﬁed model. All predictors were
assessed in the 180 days before (and including) the initiation
of a VKA, with the exception of receiving structured antico-
agulation management service, which was assessed until
Figure 1. Systematic review on signiﬁcant predictors for anticoagulation quality (TTR). AF indicates atrial
ﬁbrillation; INR, international normalized ratio; TTR, time in therapeutic range; VKA, vitamin K antagonist;
VTE, venous thromboembolism.
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Table 2. Patient Characteristics of the Study Populations
Continuous variables
Training Set (n=1663),
mean (SD)
AF Validation Set
(n=694), mean (SD)
VTE Validation Set
(n=487), mean (SD)
Age, y 77.0 (7.5) 76.5 (7.2) 75.6 (7.1)
Anticoagulation management service participation, %* 0.41 (0.49) 0.55 (0.50) 0.48 (0.50)
TTR†, INR 2–3 0.56 (0.25) 0.53 (0.27) 0.47 (0.28)
Percentage of time below range 0.32 (0.26) 0.38 (0.30) 0.43 (0.32)
Percentage of time above range 0.12 (0.14) 0.09 (0.12) 0.09 (0.13)
Mean follow-up time to assess INR, d 179.3 (121.7) 174.5 (131.0) 136.3 (117.9)
Categorical variables
Training Set (n=1663),
n (%)
AF Validation Set
(n=694), n (%)
VTE Validation Set
(n=487), n (%)
Female sex 829 (49.9) 322 (46.4) 282 (57.9)
Race
Black 45 (2.7) 44 (6.3) 54 (11.1)
White 1519 (91.3) 608 (87.6) 398 (81.7)
Other 99 (6.0) 42 (6.1) 35 (7.2)
Limited English proficiency 157 (9.4) 80 (11.5) 58 (11.9)
Patients with higher education‡
Above median 758 (45.6) 341 (49.1) 231 (47.4)
Below median 879 (52.9) 341 (49.1) 248 (50.9)
Missing 26 (1.6) 12 (1.7) 8 (1.6)
Income level‡
Above median 940 (56.5) 389 (56.1) 262 (53.8)
Below median 697 (41.9) 293 (42.2) 217 (44.6)
Missing 26 (1.6) 12 (1.7) 8 (1.6)
Distance from the nearest provider facility, miles†
<5 610 (36.7) 351 (50.6) 234 (48.1)
5–10 455 (27.4) 102 (14.7) 64 (13.1)
10–20 295 (17.7) 78 (11.2) 58 (11.9)
>20 303 (18.2) 163 (23.5) 131 (26.9)
BMI
<18.5 24 (1.4) 5 (0.7) 4 (0.8)
18.5–24.9 219 (13.2) 114 (16.4) 74 (15.2)
25–29.9 379 (22.8) 180 (25.9) 118 (24.2)
30–34.9 277 (16.7) 110 (15.9) 77 (15.8)
35–39.9 102 (6.1) 54 (7.8) 44 (9.0)
≥40 96 (5.8) 36 (5.2) 16 (3.3)
Missing 566 (34.0) 195 (28.1) 154 (31.6)
Smoking status
Current 247 (14.9) 79 (11.4) 58 (11.9)
Not current 1291 (77.6) 555 (80.0) 394 (80.9)
Missing 125 (7.5) 60 (8.7) 35 (7.2)
CHF 427 (25.7) 224 (32.3) 155 (31.8)
Epilepsy 84 (5.1) 26 (3.7) 31 (6.4)
Cancer 628 (37.8) 281 (40.5) 241 (49.5)
Continued
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Table 2. Continued
Categorical variables
Training Set (n=1663),
n (%)
AF Validation Set
(n=694), n (%)
VTE Validation Set
(n=487), n (%)
Renal dysfunction 579 (34.8) 263 (37.9) 227 (46.6)
Prior bleeding§ 364 (21.9) 166 (23.9) 148 (30.4)
Pneumonia 365 (21.9) 125 (18.0) 135 (27.7)
Drug abuse 18 (1.1) 4 (0.6) 3 (0.6)
Chronic liver disease 143 (8.6) 49 (7.1) 65 (13.3)
Psychosis 104 (6.3) 37 (5.3) 39 (8.0)
Hyperlipidemia 1131 (68.0) 488 (70.3) 320 (65.7)
Peripheral vascular
disease
283 (17.0) 109 (15.7) 77 (15.8)
Use of b blocker 1071 (64.4) 555 (80.0) 318 (65.3)
Use of ACEI 619 (37.2) 248 (35.7) 168 (34.5)
Use of metolazone 7 (0.4) 25 (3.6) 19 (3.9)
Use of opioids 665 (40.0) 307 (44.2) 298 (61.2)
Use of statins 1019 (61.3) 466 (67.1) 289 (59.3)
Use of acetaminophen 658 (39.6) 209 (30.1) 225 (46.2)
Use of antibiotics 915 (55.0) 402 (57.9) 345 (70.8)
Use of antiplatelet agents 506 (30.4) 251 (36.2) 186 (38.2)
Use of oral steroids 265 (15.9) 104 (15.0) 113 (23.2)
Influenza vaccine 534 (32.1) 227 (32.7) 154 (31.6)
PSA test 256 (15.4) 121 (17.4) 68 (14.0)
Mammography 136 (8.2) 44 (6.3) 43 (8.8)
Pap smear 41 (2.5) 17 (2.4) 16 (3.3)
Falls 171 (10.3) 53 (7.6) 63 (12.9)
Fractures 185 (11.1) 52 (7.5) 71 (14.6)
Parkinson disease 30 (1.8) 18 (2.6) 9 (1.8)
Albumin level, g/dL
≥3.5 775 (46.6) 303 (43.7) 201 (41.3)
2.5–3.49 334 (20.1) 111 (16.0) 123 (25.3)
<2.5 53 (3.2) 17 (2.5) 25 (5.1)
Missing 501 (30.1) 263 (37.9) 138 (28.3)
ALP level, U/L
≤150 1064 (64.0) 402 (57.9) 315 (64.7)
>150 73 (4.4) 25 (3.6) 26 (5.3)
Missing 526 (31.6) 267 (38.5) 146 (30.0)
Sodium level, mmol/L
>130 1387 (83.4) 529 (76.2) 391 (80.3)
≤130 18 (1.1) 12 (1.7) 6 (1.2)
Missing 258 (15.5) 153 (22.1) 90 (18.5)
eGFR, mL/min/1.73m2
≥60 736 (44.3) 285 (41.1) 225 (46.2)
30–59.9 447 (26.9) 165 (23.8) 105 (21.6)
15–29.9 49 (3.0) 32 (4.6) 18 (3.7)
Continued
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28 days after VKA initiation (immediately before the start of
the follow-up).
Performance of the Geriatric TTR Score Versus
SAMe-TT2R2
We calculated a coefﬁcient-based and simpliﬁed version of
the SAMe-TT2R2 score for each patient (see Table S1 for
details).17 Model performance was compared (1) between the
geriatric TTR score and the coefﬁcient-based SAMe-TT2R2
score and (2) between the simpliﬁed point system of the
geriatric TTR score and the simple SAMe-TT2R2 score. The
validation set was subdivided into AF and VTE populations. We
computed the AUC when predicting TTR >70%, a cutoff to
indicate good anticoagulation quality in the literature.34,35 We
then computed the AUC when predicting incidence of a
composite clinical outcome of stroke, systemic arterial
embolism, VTE, and major bleeding (see detailed deﬁnitions
in Table S2) that occurred between the 29th and 365th days
following the index date (ie, the same ascertainment period as
TTR). We also evaluated thromboembolic and bleeding events
separately. In addition, we computed Hosmer–Lemeshow
goodness-of-ﬁt statistics to assess calibration of the models.
The hypothesis testing for AUC comparison was done with
methods proposed by DeLong et al.36
Missing Data
The information on smoking and body mass index was
recorded in the study EHRs as both structured data and text
in the clinical notes. To reduce missing data, we used
natural language processing37 to extract information on
these 2 variables from the clinical notes; this approach
reduced the proportion of patients missing smoking data
from 54.4% to 7.8% and of those missing body mass index
from 38.5% to 32.2% (see Data S1 for details). For those still
missing smoking and body mass index information after
natural language processing and with other variables with
missing data, we used the missing indicator method in the
analysis.
Statistical Analyses
First, we tested the sensitivity of our results to the length of
the baseline assessment period (365 instead of 180 days)
and the deﬁnition of the new initiator of VKA (no use of
VKA in the 180 days instead of 90 days before the index
date). We calculated the Spearman correlation coefﬁcient
between the new scores based on revised strategies and
the original score to quantify discrepancies. Second, to
evaluate whether our results were sensitive to outliers or
Table 2. Continued
Categorical variables
Training Set (n=1663),
n (%)
AF Validation Set
(n=694), n (%)
VTE Validation Set
(n=487), n (%)
<15 92 (5.5) 51 (7.4) 44 (9.0)
Missing 339 (20.4) 161 (23.2) 95 (19.5)
Hospitalization length of stayk
None 571 (34.3) 245 (35.3) 100 (20.5)
1–6 d 497 (29.9) 235 (33.9) 152 (31.2)
≥7 d 595 (35.8) 214 (30.8) 235 (48.3)
Number of hospitalizationsk
0 571 (34.3) 245 (35.3) 100 (20.5)
1 621 (37.3) 261 (37.6) 179 (36.8)
≥2 471 (28.3) 188 (27.1) 208 (42.7)
Number of medications¶
<5 529 (31.8) 222 (32.0) 154 (31.6)
5–9 856 (51.5) 338 (48.7) 212 (43.5)
≥10 278 (16.7) 134 (19.3) 121 (24.9)
ACEI indicates angiotensin-converting enzyme inhibitor; AF, atrial ﬁbrillation; ALP, alkaline phosphatase; BMI, body mass index; CHF, congestive heart failure; eGFR, estimated glomerular
ﬁltration rate; INR, international normalized ratio; PSA, prostate-speciﬁc antigen; TTR, time in therapeutic range; VKA, vitamin K antagonist; VTE, venous thromboembolism.
*Percentage of patients participating in a dedicated anticoagulation management service.
†See the distribution of TTR in training and validation sets in Figure S2.
‡Based on ZIP codes of residence.
§Including all the major upper and lower gastrointestinal, and other extracranial bleeding events.
kIn the 180 days before VKA initiation.
¶At the time of VKA initiation.
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skewed the distribution of TTR, we repeated our analyses
after (1) Box–Cox transformation of TTR38 and (2) exclusion
of those with extreme outcomes (TTR=0) from the analysis.
The statistical analyses were conducted with SAS 9.4 (SAS
Institute Inc).
Table 3. The Geriatric TTR Prediction Model for
Anticoagulation Control Quality*
Predictor Coefﬁcient (SE)†
Intercept 0.583 (0.030)
AF vs VTE 0.010 (0.013)
Dedicated anticoagulation management
service: yes vs no
0.105 (0.014)
Sex, female vs male 0.016 (0.014)
Black race 0.046 (0.036)
Nonblack, nonwhite race 0.036 (0.026)
White Ref
Limited English proficiency 0.033 (0.021)
Income: below median‡ 0.009 (0.014)
Income: missing‡ 0.018 (0.047)
Income: median or higher‡ Ref
Living 10–20 miles from facility§ 0.016 (0.018)
Living 5–10 miles from facility§ 0.026 (0.016)
Living >20 miles from facility§ 0.041 (0.017)
Living <5 miles from facility§ Ref
BMI 25–29.9 0.059 (0.020)
BMI 30–34.9 0.027 (0.021)
BMI 35–39.9 0.065 (0.028)
BMI <18.5 0.057 (0.050)
BMI ≥40 0.049 (0.029)
BMI missing 0.035 (0.019)
BMI 18.5–24.9 Ref
CHF 0.019 (0.015)
Epilepsy 0.016 (0.027)
Cancer 0.026 (0.012)
Renal dysfunction 0.043 (0.015)
Prior bleedingk 0.021 (0.015)
Pneumonia 0.016 (0.016)
Drug abuse 0.073 (0.056)
Chronic liver disease 0.025 (0.021)
Psychosis 0.022 (0.024)
Hyperlipidemia 0.025 (0.014)
No. of regular medications, 5–9 0.029 (0.014)
No. of regular medications, ≥10 0.036 (0.020)
No. of regular medications, <5 Ref
Hospitalization d ≥7 d: yes vs no 0.001 (0.019)
No. of hospitalizations ≥2: yes vs no 0.001 (0.018)
Albumin 2.5–3.49 g/dL 0.014 (0.017)
Albumin <2.5 g/dL 0.075 (0.035)
Albumin missing 0.020 (0.038)
Continued
Table 3. Continued
Predictor Coefﬁcient (SE)†
Albumin ≥3.5 g/dL Ref
ALP >150 U/L 0.068 (0.029)
ALP missing 0.014 (0.037)
ALP ≤150 U/L Ref
Sodium ≤130 mmol/L 0.017 (0.056)
Sodium missing 0.078 (0.027)
Sodium >130 mmol/L Ref
eGFR 15–29.9 mL/min/1.73m2 0.038 (0.036)
eGFR 30–59.9 mL/min/1.73m2 0.003 (0.015)
eGFR <15 mL/min/1.73m2 0.070 (0.029)
eGFR missing 0.017 (0.023)
eGFR ≥60 mL/min/1.73m2 Ref
Peripheral vascular disease 0.016 (0.017)
Use of b blocker 0.028 (0.013)
Use of ACEI 0.018 (0.012)
Use of metolazone 0.075 (0.089)
Use of opioids 0.013 (0.016)
Use of statins 0.027 (0.014)
Use of acetaminophen 0.024 (0.016)
Use of antibiotics 0.021 (0.013)
Use of antiplatelet agents 0.027 (0.015)
Use of oral steroids 0.012 (0.017)
Influenza vaccine 0.020 (0.012)
PSA test 0.037 (0.018)
Mammography 0.061 (0.022)
Pap smear 0.048 (0.037)
Falls 0.021 (0.021)
Fractures 0.013 (0.021)
Parkinson disease 0.097 (0.043)
ACEI indicates angiotensin-converting enzyme inhibitors; AF, atrial ﬁbrillation; ALP,
alkaline phosphatase; BMI, body mass index; CHF, congestive heart failure; eGFR,
estimated glomerular ﬁltration rate; PSA, prostate-speciﬁc antigen; TTR, time in
therapeutic range; VTE, venous thromboembolism.
*Quantiﬁed by international normalized ratio (INR) time in therapeutic range (TTR), see
the distribution of TTR in training and validation sets in Figure S2.
†Unstandardized coefﬁcients based on a lasso regression model including all the
variables listed in this table.
‡Based on the mean income level of the ZIP code the patients resided in.
§Average distance based on ZIP codes from the nearest facility in the network.
kIncluding all the major upper and lower gastrointestinal, and other extracranial bleeding
events.
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Results
Systematic Review
From a total of 3692 studies, we selected 16 articles
(Figure 1 summarizes the search and selection process).
Among them, 11 articles investigated patients taking VKA for
nonvalvular AF,17,18,20,22,39–45 4 for mixed indica-
tions19,21,46,47 and 2 for VTE.18,48 Based on these selected
articles, we identiﬁed 8 positive and 42 negative predictors
(Table 1). To enrich the candidate predictor pool, we added
23 variables based on clinical knowledge (see Table S3 for the
full list of candidate predictors and their deﬁnitions).
Patient Characteristics of the Study Population
Among 14250 VKA new initiators with at least 180 days of
Medicare enrollment and 1 EHR encounter in the study
system, we selected the study cohort with at least 5 INRs
recorded in our database, including 1663 patients in the
training set, 694 in the AF validation set, and 487 in the VTE
validation set. The distribution of combined comorbidity score
was similar in patients with versus without 5 INRs with a
mean standardized difference of 0.02 between proportions of
all combined comorbidity score categories in those included
versus excluded (Figure S1). The mean TTR was 0.47 to 0.56
in our training and validation sets (Table 2 and Figure S2). We
observed modest differences in some predictors in AF versus
VTE validation populations (eg, higher prevalence of cancer
and more use of antibiotics in the VTE; Table 2).
Prediction Models for TTR
From 50 predictors identiﬁed in the systematic review and 23
additional variables, we built the new geriatric TTR score with
42 predictors through lasso regression (R2=0.19; Table 3).
The simpliﬁed model included a total of 7 variables (R2=0.14).
We summarized these variables using the acronym PROSPER
(Pneumonia, Renal dysfunction, Oozing blood [prior bleeding],
Staying in hospital ≥7 days, use of Pain medications, lack of
Enhanced [dedicated and structured] anticoagulation care, Rx
for antibiotics; see Table 4 and Table S3 for detailed
deﬁnitions). There was no signiﬁcant difference between the
AUCs of PROSPER versus the full geriatric TTR model
predicting TTR >70% in the validation set (AUC 0.678 versus
0.680, P=0.86 for difference). The 2 most inﬂuential predic-
tors of TTR were lack of participation in a dedicated
anticoagulation management service (assigned 4 points) and
renal dysfunction (assigned 2 points). The rest of the variables
were assigned 1 point each.
Comparison of Performance: SAMe-TT2R2 Versus
Geriatric TTR Score
In the training set, the AUC for the geriatric TTR score
predicting TTR >70% (AUC=0.71) was substantially larger than
that for coefﬁcient-based SAMe-TT2R2 (AUC=0.57, P<0.001
for difference); the AUC for the geriatric TTR score predicting
the primary clinical outcome (AUC=0.65) was signiﬁcantly
larger than that for SAMe-TT2R2 (AUC=0.53, P<0.001 for
difference). The results were similar in the validation set
(Figure 2). This pattern was consistent when the validation set
was subdivided into AF and VTE validation sets (Table 5). We
also found similar ﬁndings when the composite clinical
outcome was subdivided into thromboembolic versus bleed-
ing outcomes (Table S4). The Hosmer–Lemeshow goodness-
of-ﬁt test for predicting TTR >70% conﬁrmed good calibration
for the both the full geriatric model and coefﬁcient-based
SAMe-TT2R2 in the training and validation sets (Table S5).
Comparison of Performance: SAMe-TT2R2 Simple
Scoring System Versus PROSPER
In the training set, the AUC for PROSPER predicting TTR >70%
(AUC=0.67) was substantially larger than that for SAMe-TT2R2
(AUC=0.55, P<0.001 for difference); the AUC for PROSPER
predicting the primary clinical outcome (AUC=0.62) was
signiﬁcantly larger than that for SAMe-TT2R2 (AUC=0.52,
P<0.001 for difference). A similar pattern was observed in the
AF and VTE validation sets when predicting both types of
outcomes (Table 5). Patients stratiﬁed by PROSPER had a
clear decreasing trend of mean TTR, ranging from 0.71 to
0.30, in both the training and validation sets (Table 6).
Table 4. Simpliﬁed Geriatric Prediction Score for
Anticoagulation Control Quality*: PROSPER
Predictor Coefﬁcient (SE)† Point
Intercept 0.719 (0.012) 
Pneumonia 0.030 (0.015) 1
Renal dysfunction‡ 0.068 (0.013) 2
Oozing blood (bleeding history) 0.026 (0.015) 1
Staying in hospital ≥7 d 0.029 (0.015) 1
Pain medications 0.037 (0.013) 1
No Enhanced anticoagulation care§ 0.122 (0.012) 4
Rx for antibiotics 0.030 (0.013) 1
All variables should be assessed in the 6 mo before initiating a VKA, except for no
enhanced anticoagulation care, which was assessed at the time of initiation. PROSPER
indicates Pneumonia, Renal dysfunction, Oozing blood [prior bleeding], Staying in
hospital ≥7 days, use of Pain medications, lack of Enhanced [dedicated and structured]
anticoagulation care, Rx for antibiotics; VKA, vitamin K antagonist.
*Quantiﬁed by international normalized ratio time in therapeutic range (TTR).
†Unstandardized coefﬁcients based on a model selected based on a Bayesian
information criterion.
‡Renal dysfunction was deﬁned as having records for acute kidney injury, chronic kidney
disease, or end-stage kidney disease in the prior 180 days.
§Lack of participation (no access or plan) in a dedicated anticoagulation management
service when initiating a VKA.
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Sensitivity Analyses
After changing the length of baseline assessment period
from 180 to 365 days, the revised prediction score was
highly correlated with the original one (Spearman coefﬁ-
cient=0.89). After deﬁning new initiation of VKA as no use in
the 180 days rather than 90 days before the index date, the
revised prediction score was highly correlated with the
original one (Spearman coefﬁcient=0.99). The performance
of these revised models was similar to that of the original
model (Table S6). After Box–Cox transformation, the distri-
bution of TTR became more symmetric (Fisher-Pearson
skewness coefﬁcient49 reduced by 46%), resulting in a
prediction score highly correlated with the predicted value
generated by the original model (Spearman coefﬁ-
cient=0.99). Similar patterns were found when excluding
those with TTR 0 (Table S6).
Discussion
We developed and validated a new prediction score in the
older adult population. Our geriatric TTR score included 42
predictors, and the simpliﬁed clinical scoring system,
PROSPER, had 7 variables. The geriatric TTR score and
Figure 2. Comparison of AUC: new geriatric score superior to SAMe-TT2R2. A, Predicting TTR >70%. B,
Predicting clinical outcomes. *Composite outcomes of incident stroke, systemic embolism, VTE, and major
bleeding events. AF indicates atrial ﬁbrillation; AUC, area under the receiver operating characteristic curve;
INR, international normalized ratio; TTR, time in therapeutic range; VTE, venous thromboembolism.
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PROSPER outperformed the corresponding coefﬁcient-based
and simple version of SAMe-TT2R2, available for the past
4 years, when predicting TTR ≥70% and thromboembolic and
bleeding outcomes for those aged ≥65 years. The perfor-
mance of PROSPER was not signiﬁcantly worse than that of
the full model in the validation set.
Physicians can use geriatric TTR scores to identify patients
with good predicted TTR (>70%) as good candidates for VKA
therapy for nonvalvular AF or VTE; otherwise, a DOAC may be
preferred unless contraindicated. It is feasible to develop an
automated program in an EHR system for computing the
predicted TTR based on the full model as a clinical decision
support tool; otherwise, PROSPER can be readily calculated
without an aid. Our ﬁndings suggest that a PROSPER score >2
is predictive of having poor TTR; therefore, initiating a VKA
may not be ideal. This cut point is associated with reasonable
speciﬁcity (75%) for TTR >70% and sensitivity (85%; Table 7)
for TTR <50% (another cut point suggested in the literature to
indicate poor anticoagulation quality34). Alternatively, the
Table 5. Comparison of Model Performance of Original SAMe-TT2R2 and Geriatric TTR Score
Optimized Prediction Models Simpliﬁed Prediction Models
SAMe-TT2R2*
AUC (95% CI)
Geriatric TTR Score
AUC (95% CI)
P for
Difference
SAMe-TT2R2
†
AUC (95% CI)
PROSPER‡
AUC (95% CI)
P for
Difference
Prediction TTR >70%, training set 0.57 (0.54–0.59) 0.71 (0.68–0.73) <0.001 0.55 (0.52–0.58) 0.67 (0.64–0.69) <0.0001
Prediction TTR >70%, AF validation set 0.57 (0.52–0.61) 0.66 (0.62–0.70) 0.0011 0.58 (0.53–0.62) 0.67 (0.62–0.71) 0.0016
Prediction TTR >70%, VTE validation set 0.57 (0.51–0.63) 0.74 (0.69–0.79) <0.001 0.59 (0.54–0.65) 0.71 (0.66–0.77) 0.0003
Prediction clinical outcomes,§ training set 0.53 (0.49–0.56) 0.65 (0.62–0.69) <0.001 0.52 (0.49–0.56) 0.62 (0.58–0.66) <0.0001
Prediction clinical outcomes,§ AF validation set 0.60 (0.54–0.66) 0.74 (0.69–0.79) <0.001 0.60 (0.55–0.66) 0.73 (0.68–0.77) <0.0001
Prediction clinical outcomes,§ VTE validation set 0.57 (0.51–0.63) 0.67 (0.61–0.72) 0.01 0.59 (0.53–0.65) 0.65 (0.60–0.71) 0.098
AF indicates atrial ﬁbrillation; AUC, area under receiver operating characteristic curve; CI, conﬁdence interval; PROSPER, Pneumonia, Renal dysfunction, Oozing blood [prior bleeding],
Staying in hospital ≥7 days, use of Pain medications, lack of Enhanced [dedicated and structured] anticoagulation care, Rx for antibiotics; TTR, time in therapeutic range; VTE, venous
thromboembolism.
*Based on original coefﬁcients.
†Simple scoring system of SAMe-TT2R2.
‡Simpliﬁed geriatric TTR scoring system, see details in Table 4.
§Composite outcomes of incident stroke, systemic embolism, VTE, and major bleeding events.
Table 6. Mean TTR by Simpliﬁed New Geriatric Score
Simpliﬁed
Geriatric
Score
(PROSPER)*
Training Set (n=1663) Validation Set (n=1033)
n (%)
Mean TTR
(SD) n (%)
Mean TTR
(SD)
0 154 (9.3) 0.71 (0.17) 106 (10.3) 0.70 (0.18)
1 148 (8.9) 0.67 (0.20) 99 (9.6) 0.63 (0.19)
2 118 (7.1) 0.67 (0.18) 121 (11.7) 0.61 (0.21)
3 79 (4.8) 0.64 (0.18) 78 (7.6) 0.58 (0.23)
4 225 (13.5) 0.59 (0.25) 112 (10.8) 0.56 (0.24)
5 217 (13.0) 0.55 (0.25) 102 (9.9) 0.49 (0.31)
6 202 (12.1) 0.55 (0.25) 115 (11.1) 0.49 (0.28)
7 162 (9.7) 0.52 (0.25) 77 (7.5) 0.34 (0.30)
8 128 (7.7) 0.45 (0.28) 74 (7.2) 0.32 (0.26)
9 104 (6.3) 0.43 (0.27) 58 (5.6) 0.31 (0.28)
10 91 (5.5) 0.41 (0.26) 58 (5.6) 0.43 (0.31)
11 35 (2.1) 0.35 (0.25) 33 (3.2) 0.30 (0.23)
PROSPER indicates Pneumonia, Renal dysfunction, Oozing blood [prior bleeding], Staying
in hospital ≥7 days, use of Pain medications, lack of Enhanced [dedicated and
structured] anticoagulation care, Rx for antibiotics; TTR, time in therapeutic range.
*See details in Table 4.
Table 7. Sensitivity and Speciﬁcity in the Validation Set
(AF and VTE)
Cutoff of
Simpliﬁed
Geriatric
Score
(PROSPER)*
TTR >70% TTR <50%
Sensitivity
(%)
Speciﬁcity
(%)
Sensitivity
(%)
Speciﬁcity
(%)
0 19.5 93.4 97.7 15.9
1 31.4 84.7 92.6 28.7
2 47.1 74.6 85.2 43.5
3 56.0 67.6 79.4 52.3
4 68.9 57.6 70.5 64.6
5 79.5 48.0 59.2 73.4
6 89.1 36.2 46.6 83.6
7 91.8 26.9 35.5 88.4
8 93.5 17.6 22.7 91.5
9 95.2 10.4 13.0 94.2
10 99.7 4.3 5.8 98.7
11 100.0 0 0 100.0
AF indicates atrial ﬁbrillation; PROSPER, Pneumonia, Renal dysfunction, Oozing blood
[prior bleeding], Staying in hospital ≥7 days, use of Pain medications, lack of Enhanced
[dedicated and structured] anticoagulation care, Rx for antibiotics; TTR, time in
therapeutic range; VTE, venous thromboembolism.
*Deﬁning patients with scores lower than or equal to this cutoff as having TTR >70% and
those with scores higher than the cut point as having TTR <50%.
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categorization of PROSPER as 0 to 2, 3 to 6, and ≥7
approximately subdivided the population into tertiles that
correlated well with TTR. These 3 categories may be used to
indicate low, moderate, and high risk of having poor TTR
(Table 8). Our work highlights the importance of a structured
approach to warfarin management; lack of a dedicated
anticoagulation management service was found to be the
strongest predictor of poor TTR. This ﬁnding is in line with
several prior studies in which structured anticoagulation care
was shown to improve TTR and to reduce risk of complica-
tions.50–53 In the current era when DOACs are available,
unstructured warfarin management is a particularly unattrac-
tive treatment option. If DOAC treatment is not possible and a
patient has a PROSPER score >2, providers should encourage
patient participation in a dedicated anticoagulation manage-
ment service or some equivalently well-organized warfarin
treatment setting (eg, a practice with a nurse dedicated to
managing warfarin). Renal dysfunction, deﬁned as the pres-
ence of acute kidney injury, chronic kidney disease, or end-
stage kidney disease in the prior 180 days, was also found to
be an important predictor of poor TTR. The anticoagulation
decision is particularly difﬁcult in AF patients with renal
dysfunction, for whom there is uncertainty as to the net
beneﬁt of warfarin or DOACs with poor renal function. One
approach can be to favor use of a DOAC that is less renally
excreted (eg, apixaban) with necessary dose adjustment.
Our score can also be helpful in a research context. First,
researchers can evaluate the potential treatment-effect hetero-
geneity by levels of predicted anticoagulation quality based on
the full model with a computer program. This assessment can
provide direct evidence for choosing the ideal candidates for
VKA versus DOACs based on the pretreatment characteristics
predictive of anticoagulation quality. Next, our score can be
used as a proxy adjustment tool for confounding by anticoag-
ulation control quality. This adjustment is otherwise difﬁcult
because calculating TTR requires intensive INR recording in the
study databases, which are often incomplete or nonexistent.
Because some researchers do not have information on
biophysiologic variables, we also presented an alternative
model excluding these variables that requires additional testing
(Table S7). This alternative model had performance similar to
the geriatric TTR score (data not shown).
We have demonstrated that the performance of the new
geriatric TTR score was clearly superior to that of SAMe-TT2R2
in the older adult population. The authors of SAMe-TT2R2
demonstrated good discrimination performance only when
predicting those with TTR <5th percentile but not for those
with TTR <25th percentile (AUC=0.58).17 However, the latter
is closer to the clinical relevant cut points (eg, TTR >70%
usually composes about 30% to 40% of the population17,18,34).
Because the majority of VKA users are older adults3,18 who
are also more vulnerable to developing bleeding complica-
tions,54 we developed an alternative score dedicated to
patients aged ≥65 years. We built a prediction model for both
nonvalvular AF and VTE indications because prior studies
found that AF and VTE patients share many risk factors for
TTR18 and because including interaction terms with the VKA
indications did not materially improve the model in our
analysis. We validated the performance of our model in AF
and VTE populations separately and found consistent results.
There are some important limitations. We used linked
claims EHR data for higher data quality: The claims data
provided comprehensive data across care settings, and EHRs
provided necessary clinical information to ascertain TTR and
important predictors. However, requiring overlap of the 2
databases reduces our sample size substantially and limits
our ability to investigate each clinical outcome individually.55
Besides, for biophysiologic variables (eg, body mass index,
albumin levels), we had 29% to 34% people with missing data
in the relevant period. We handled it by the missing indicator
method because not having certain tests done could, by itself,
be informative of the general health state, and this approach
allows use of these scores even if some variables are not
available. As a sensitivity analysis, the scores not including
these variables with missing data were highly correlated with
the original one and had similar model performance (data not
shown). In addition, some of the possible determinants of TTR
are not available in our data sets, such as diet information and
genetic proﬁles associated with warfarin pharmacokinetics,
which may limit our model performance. Consequently, our
prediction scores should be used as an aid, not as the only
ground for decision-making. Next, we chose to build one
prediction model for both nonvalvular AF and VTE indications
because prior studies found that AF and VTE patients have
many common risk factors for poor anticoagulation qualilty.18
We validated the performance of this score in AF and VTE
populations separately and found consistent results. Nonethe-
less, we acknowledge the alternative approach to build
separate models for different indications, which may increase
speciﬁcity at the cost of simplicity and applicability. Last, the
Table 8. TTR by the Simpliﬁed Geriatric Score Categories
Simpliﬁed
Geriatric
Score
(PROSPER)
Training Set Validation Set (AF and VTE)
n (%) Mean (SD) n (%) Mean (SD)
0–2 420 (25.3) 0.69 (0.18) 326 (31.6) 0.64 (0.20)
3–6 723 (43.5) 0.57 (0.25) 407 (39.4) 0.52 (0.27)
≥7 520 (31.3) 0.45 (0.27) 300 (29.0) 0.34 (0.28)
Total 1663 0.56 (0.25) 1033 0.51 (0.27)
AF indicates atrial ﬁbrillation; PROSPER, Pneumonia, Renal dysfunction, Oozing blood
[prior bleeding], Staying in hospital ≥7 days, use of Pain medications, lack of Enhanced
[dedicated and structured] anticoagulation care, Rx for antibiotics; TTR, time in
therapeutic range; VTE, venous thromboembolism.
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predictors identiﬁed in our study should not be interpreted as
having causal effect on anticoagulation quality because they
could be merely the markers or proxies of the real causal
factors.
In conclusion, we developed and validated a prediction
score for anticoagulation control quality quantiﬁed by TTR in
the older adult population. It outperformed the published
score, SAMe-TT2R2, in patients aged ≥65 years when
predicting TTR as well as thromboembolic and bleeding
events. The full model of the geriatric TTR score can be used
as an embedded algorithm within an EHR or for a research
study. The simpliﬁed scoring system, PROSPER, had compa-
rable performance and can be used in daily practice to help
choose the best candidates to receive VKA therapy.
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Supplemental Material 
  
Data S1. 
Natural language processing to improve missing data 
We extracted smoking and BMI information from free text clinical notes using MTERMS 
(Medical Text Extraction, Reasoning and Extraction System)1, a modular, pipeline-based NLP 
system for identifying clinical terms in unstructured medical record text. MTERMS takes as 
input a text file containing a single clinical note which it decomposes into sections (e.g., “History 
of Present Illness”, “Impression and Plan”), when applicable. Sections are further decomposed to 
sentences, which are then tokenized and processed through a series of lexical lookup- and regular 
expression-based modules. MTERMS applies and supports both machine learning and rule-based 
algorithms for classification tasks. In this project, we used a rule-based approach.  
 
To extract smoking status, we used a lexicon of terms found to be indicative of or associated 
with smoking status. This set of terms was constructed and used by MTERMS to extract 
smoking status as part of a study to predict hospital readmission2. Terms were compiled from 
various clinical terminologies and guidelines (e.g., SNOMED-CT, Public Health Service 
Tobacco Use and Dependence Guidelines). Synonyms, abbreviations, and other lexical 
variations were manually added to the list by a team of clinical informaticians. Following term 
extraction, MTERMS identifies and processes certain contextual information associated with the 
extracted terms, including negation (e.g., “non-smoker”, “quit smoking”) and family history 
information (e.g., “patient’s father smokes”). A regular expression-based classifier was applied 
to the extracted output to differentiate between patients who currently smoke, patients who 
previously smoked but do not currently smoke, and patients who have never smoked. 
 
BMI information was extracted with a similar approach. First, we used MTERMS to perform a 
lexical search for the terms “BMI”, “body mass index”, and a small set of lexical variations 
thereof. We also used MTERMS to search for height and weight information using a lexicon 
compiled from clinical terminologies (e.g., LOINC®)3 and manually supplemented with 
synonyms, abbreviations, and other lexical variations. Once terms were identified, MTERMS 
applied a set of regular expressions to locate and extract the actual values associated with the 
extracted terms, as well as the units in which the values were reported, if applicable. If both 
height and weight values (and their corresponding units) were identified, an additional post-
processing step was applied to calculate the BMI. 
 
 
  
Table S1. SAMe-TT2R2 original model4 
Variable Unstandardized coefficient 
Female sex -0.04 
Age<50 years old -0.14 
Age 50-60 years old -0.04 
Non-white race -0.09 
Tobacco smoking within 2 years -0.04 
More than two comorbidities* -0.04 
Β-blocker use 0.03 
Verapamil use 0.05 
Amiodarone use -0.03 
* more than two of the following: hypertension, diabetes, coronary artery disease/myocardial 
infarction, peripheral arterial disease, congestive heart failure, previous stroke, pulmonary disease, 
and hepatic or renal disease.  
 
SAMe-TT2R2 simple scoring system4 
Acronym Definition Points 
S Female sex 1 
A Age< 60 years old 1 
Me More than two comorbidities* 1 
T Treatment with interacting drug, e.g. amiodarone 1 
T Tobacco smoking within 2 years 2 
R Non-white race 2 
* more than two of the following: hypertension, diabetes, coronary artery disease/myocardial 
infarction, peripheral arterial disease, congestive heart failure, previous stroke, pulmonary disease, 
and hepatic or renal disease.  
 
 
  
Table S2. Definitions of clinical outcomes 
Outcome Hospital Discharge Code(s) Comments 
Primary Outcome: a composite outcome of stroke, systemic embolism, deep vein thrombosis, 
pulmonary Embolism, and major extracranial bleeding listed below 
Stroke As primary ICD-9 discharge diagnosis (Dx): 
430.x  Subarachnoid hemorrhage (SAH) 
431.x  Intracranial hemorrhage (ICH) 
433.x1  Occlusion and stenosis of precerebral arteries 
with cerebral infarction 
434.x1  Occlusion and stenosis of cerebral arteries with 
cerebral infarction 
436.x  Acute, but ill-defined cerebrovascular events  
In Tennessee Medicaid 
enrollees aged 50-84, the 
algorithm had PPV of  
97% for primary 
discharge diagnoses and 
89% for primary and 
secondary5 
See Mini-Sentinel report 
for PPV for individual 
codes or other 
algorithms6 
Systemic 
embolism 
ICD-9 Diagnoses: 
  444.x    Arterial embolism 
362.3x  Retinal vascular occlusion 
996.7x  Other complications of internal (biologic or 
synthetic) prosthetic device, implant, and graft 
(including but not limited to embolism or thrombus) 
997.7x Vascular complications of other vessels 
Mesenteric artery (997.71) 
Renal artery (997.72) 
Other vessels (997.79) 
415.1x Pulmonary embolism and infarction 
No validation studies 
available. Codes are 
thought to be specific 
because of the 
substantial clinical 
symptomatic and 
required therapy.  
Deep vein 
thrombosis 
(DVT) 
Validated algorithm: 
ICD-9 451.1x  (Phlebitis and thrombophlebitis of deep 
vessels of lower extremities) 
ICD-9 451.2x (of lower extremities, unspecified) 
ICD-9 451.81 (of Iliac vein) 
ICD-9 451.9x  (of unspecified site) 
ICD-9 453.1x  (thrombophlebitis migrans) 
ICD-9 453.2x ( venous embolism and thrombosis of 
vena cava) 
ICD-9 453.8x (venous embolism and thrombosis of 
other specified veins) 
Algorithm for Deep 
vein thrombosis (DVT): 
ICD-9 codes of 451.1, 
451.2, 451.81, 451.9, 
453.1, 453.2, 453.8, 
453.9 [hospital 
discharge, any 
position] had PPV of 
0.72 and specificity > 
0.99 in Medicare 
population7 
 
 
Outcome Hospital Discharge Code(s) Comments 
ICD-9 453.9x (venous embolism and thrombosis of 
unspecified site) 
Not in the validated algorithm but will be included 
following Mini-Sentinel recommendation for VTE 
outcome: 
ICD-9 453.40 (Venous embolism and thrombosis of 
unspecified deep vessels of lower extremity (includes 
DVT) 
ICD-9 453.41 (Venous embolism and thrombosis of 
deep vessels of proximal lower extremity (includes 
femoral, iliac, popliteal, thigh, and upper leg) 
ICD-9 453.42 (Venous embolism and thrombosis of 
deep vessels of distal lower extremity (includes calf, 
lower leg, peroneal, and tibia) 
ICD-9 453.0 (Hepatic vein thrombosis) 
Mini-Sentinel: while 
using ICD-9 codes 
415.x (PE), 451.x and 
453.x (DVT) as a VTE 
event yielded the 
highest PPV, for a 
specific event (DVT or 
PE) PPV was lower; 
therefore, the 
performance of 
algorithms depends on 
a population studied8 
Pulmonary 
Embolism (PE) 
ICD-9 415.1x (pulmonary embolism and infarction) 
 
PPV of 72% in a 
community sample (45 
YO and older)9  
Major 
extracranial 
bleeding 
Major upper GI bleed, major lower and unspecified GI 
bleed, major urogenital bleed, major other bleed (for 
codes see component outcomes below) 
No validation studies 
available for this 
outcome 
Major GI 
bleeding 
Major upper GI bleeding, major lower/unspecified GI 
bleeding (for codes see component outcomes below) 
No validation studies 
available for this 
outcome 
Major upper GI 
bleed  
ICD-9 diagnoses:  
531.0x (acute gastric ulcer with hemorrhage 
with/without obstruction) 
531.2x (with hemorrhage and perforation with/without 
obstruction) 
531.4x (chronic or unspecified gastric ulcer with 
hemorrhage with/without obstruction) 
531.6x (with hemorrhage and perforation with/without 
obstruction) 
532.0x (acute duodenal ulcer with hemorrhage 
with/without obstruction) 
532.2x (with hemorrhage and perforation with/without 
obstruction) 
532.4x (chronic or unspecified duodenal ulcer with 
hemorrhage with/without obstruction) 
532.6x (with hemorrhage and perforation with/without 
obstruction) 
533.0x (acute peptic ulcer of unspecified site with 
hemorrhage with/without obstruction) 
PPV of 87.8% in 
commercially-insured 
population10 
Outcome Hospital Discharge Code(s) Comments 
533.2x (with hemorrhage and perforation with/without 
obstruction) 
533.4x (chronic or unspecified peptic ulcer of 
unspecified site with hemorrhage with/without 
obstruction) 
533.6x (with hemorrhage and perforation with/without 
obstruction),  
534.0x (acute gastrojejunal ulcer with hemorrhage 
with/without obstruction) 
534.2x (with hemorrhage and perforation with/without 
obstruction) 
534.4x (chronic or unspecified gastrojejunal ulcer with 
hemorrhage with/without obstruction) 
534.6x (with hemorrhage and perforation with/without 
obstruction) 
578.0 (hematemesis) OR 
ICD-9 procedure code 44.43 (endoscopic control of 
gastric or duodenal bleeding) OR 
CPT code 43255 (upper gastrointestinal endoscopy 
including esophagus, stomach, and either the 
duodenum and/or jejunum as appropriate with control 
of bleeding, any method) 
Major lower GI 
bleeding 
Lower GI/unspecified GI site bleed11: 
Diverticulosis of small intestine with hemorrhage: 
562.02 
Diverticulitis of small intestine with hemorrhage: 
562.03 
Diverticulosis of colon with hemorrhage: 562.12 
Diverticulitis of colon with hemorrhage: 562.13 
Hemorrhage of rectum and anus: 569.3x 
Angiodysplasia of intestine with hemorrhage: 569.85 
Blood in stool: 578.1x 
Hemorrhage of GI tract, unspecified: 578.9 
 
PPVs for individual 
codes11: 
562.12 – 91.7% 
562.13 – 66.7%  
569.3 - 71.4% 
569.85 – 100% 
578.1 -  81.8% 
578.9 -88.2% 
Major 
urogenital 
bleed 
ICD-9 diagnoses: 
Hematuria: ICD-9 Dx: 599.7  
Excessive/frequent menstruation: ICD-9 Dx  626.2x and 
secondary diagnosis indicating acute bleeding: anemia 
(280.0, 285.1, 285.9), orthostasis (458.0), syncope 
(780.2)11  
PPVs for individual 
codes11: 
599.7 -  75.0% 
626.2 – 100% (2 
cases)11 
Other major 
bleeds 
Other major bleeds11: 
Hemathrosis: 719.1x 
Hemopericardium: 423.0x 
Hemoptysis: 786.3x 
Epistaxis: 784.7x 
Hemorrhage not specified 459.0x 
PPVs for individual 
codes11: 
719.1x – 100% 
786.3x – 80% 
784.7x – 100% 
459.0x – 100% 
Outcome Hospital Discharge Code(s) Comments 
Acute posthemorrhagic anemia 285.1x 285.1x – 100% 
 
  
Table S3. Definitions of predictors for anticoagulation control quality 
Predictors Definition* Comments 
Age By category (65-74.9, 75-84.9, ≥85)  
Sex Female, Male  
Use of 
Metolazone 
Use of Metolazone (generic name of a diuretic)  
Marital_Status  use the levels as recorded plus a missing category (available in the 
EHR raw demographic table with the variable name 
“Marital_Status”) 
 
Language use the levels as recorded plus a missing category (available in the 
EHR raw demographic table with the variable name “Language”) 
 
Median 
household 
income based on 
patient’s zipcode 
Quartiles of mean income based on zipcode using 2010 Census for 
ZIP code level variables and cross walk between zip codes and ZIP 
Code Tabulation Areas (ZCTAs) file that was obtained at: 
http://mcdc.missouri.edu/allabout/zipcodes_2010supplement.sht
ml for data after 2010 
 
Distance to MGH 
sites 
Classify zip codes based on the 4 groups in the sheet:  <5, 5-9.9, 10-
19.9, and >20 miles 
 
Distance to BWH 
sites 
Classify zip codes based on the 4 groups in the sheet:  <5, 5-9.9, 10-
19.9, and >20 miles 
 
Anemia 
280.xx Iron deficiency anemia 
281.xx Other deficiency anemias  
282.xx Hereditary hemolytic anemias 
283.xx Acquired hemolytic anemias  
284.xx Aplastic anemia and other bone marrow failure syndromes  
285.xx Other and unspecified anemias 
 
Prior valve 
surgery 
ICD-9 Dx code of V42.2 (heart valve replaced by transplant), V43.3 
(heart valve replaced  by a mechanical device/prosthesis) OR ICD-9 
procedure code 35.1x (open heart valvuloplasty without 
replacement), 35.2x (replacement of heart valve),  OR one of the 
following CPT codes:  33660-33665 (atrioventricular valve repair) 
33400-33403 (aortic valve valvuloplasty) 
33420-33430 (mitral valve repair/valvuloplasty/replacement) 
33463-33468 (tricuspid valve 
repair/valvuloplasty/replacement) 
33496 (prosthetic valve dysfunction repair) 
 
Tobacco 
smoking 
As recorded in the EHR, categorized as current, non-current, or 
missing 
 
Predictors Definition* Comments 
  Race   As the original categorization in the claims data, categorized as 
white, black, and others 
 
Hypertension At least 1 Dx of ICD-9 codes 401.x – 405.x  
OR at least 1 dispensing of a CCB, ACEI, ARB, BB, a thiazide diuretic 
or a direct antihypertensive agent 
 
Diabetes At least 2 outpatient diagnoses of DM (ICD-9 250.X (diabetes)) OR 1 
hospital discharge Dx of DM OR 1 diagnosis of DM plus an insulin or 
oral antidiabetic dispensing 
 
Heart failure 
(CHF) 
1 inpatient or 2 outpatient claims with any of ICD-9 codes: 428.x, 
398.91, 402.01, 402.11, 402.91, 404.01, 404.11, 404.91, 404.03, 
404.13, 404.93 
Validated in 
Medicare 
algorithm: 
Hospital 
discharge 
ICD-9 codes: 
428.x, 
398.91, 
402.01, 
402.11, 
402.91, 
404.01, 
404.11, 
404.91, 
404.03, 
404.13, 
404.93 
PPV  0.97, 
Spec. 0.97, 
Sens. 0.767 
Coronary 
Artery Disease 
(CAD)/ 
Previous MI 
ICD-9 Dx: 411.x-414.x, 429.2 or V45.81  
 
 
Prior stroke ICD-9 codes:  433.xx, 434.x, 435.x, 436.x, 437.x  
Peptic Ulcer 
Disease 
Diseases of esophagus: 530.1x – 530.4x, 530.8x, 530.9x 
Gastric ulcer: 531.x 
Duodenal ulcer: 532.x 
Peptic ulcer: 533.x 
Acute gastritis: 535.0x 
Other specified gastritis: 535.4x 
Unspecified gastritis and gastroduodenitis: 535.5x 
Duodenitis: 535.6x 
 
Predictors Definition* Comments 
Prior bleeding: any of the following bleeding events  
Upper GI 
bleed 
ICD-9 diagnosis: 531.0x, 531.2x, 531.4x, 531.6x 
532.0x, 532.2x, 532.4x, 532.6x, 533.0x, 533.2x, 533.4x, 533.6x,  
534.0x, 534.2x, 534.4x, 534.6x, 578.0 OR 
ICD-9 procedure code 44.43 OR 
CPT code 43255 
 
Lower/ 
unspecified GI 
bleed 
ICD-9 diagnoses: 562.02, 562.03, 562.12, 562.13, 568.81, 569.3, 
569.83, 569.85, 569.86 
578.1x, 578.9 
 
Urogenital 
bleed 
ICD-9 diagnoses: 
Hematuria: ICD-9 Dx: 599.7  
Excessive/frequent menstruation: ICD-9 Dx 626.2x AND secondary 
diagnosis indicating acute bleeding: anemia (280.0, 285.1, 285.9), 
orthostasis (458.0), syncope (780.2)  
 
Other bleeds Hemathrosis: 719.1x 
Hemopericardium: 423.0x 
Hemoptysis: 786.3x 
Epistaxis: 784.7x 
Hemorrhage not specified: 459.0x 
Acute posthemorrhagic anemia:  285.1 
 
Peripheral 
Vascular 
disease or PVD 
surgery 
1 inpatient or 2 outpatient claims with any of the following codes: 
ICD9 diagnosis: 
440.20 - 440.24, 440.29 – 440.32,  440.3, 443.9   
             
ICD9 procedure: 
38.08, 38.09, 38.18, 38.48, 38.49, 39.25, 39.5, 39.9, 84.10 - 84.17  
 
HCPCs: 
35256, 35286, 35351, 35355, 35361, 35363, 35371, 35372, 35381, 
35454, 35456, 35459, 35470, 35473, 35474, 35482, 35483, 35485, 
35492, 35493, 35495, 35521, 35533, 35541, 35546, 35548, 35549, 
35551, 35556, 35558, 35563, 35565, 35566, 35571, 35621,  35623, 
35641, 35646, 35647, 35650, 35651, 35654, 35656, 35661, 35663, 
35666, 35671, 27590, 27591, 27592, 27594, 27596, 27880, 27881, 
27882, 27884, 27886, 27888             
 
Prior liver 
disease 
ICD-9 diagnosis: 
070.x viral hepatitis 
571.x chronic liver disease and cirrhosis 
 
Predictors Definition* Comments 
572.x liver abscess and sequalae of chronic liver disease 
573.x other disorders of liver 
456.0 – 456.2x esophageal varices 
155.0 primary cancer of liver 
155.1 cancer of intrahepatic bile ducts 
155.2 cancer of liver not specified as primary or secondary 
576.8 cholestasis 
ICD-9 procedure codes: 
39.1 intra-abdominal venous shunt 
42.91 ligation of esophageal varices 
 
Renal 
Dysfunction 
 
Acute renal disease (see below) 
Chronic renal disease (see below) 
Diabetic nephropathy (see below) 
Hypertensive nephropathy (see below) 
Miscellaneous Renal Insufficiency (see below) 
or 
ESRD (see below) 
 
This 
definition of 
renal 
dysfunction 
is based on 
prior work12, 
13 and will be 
used for 
covariate 
adjustment. 
It is a 
combination 
of several 
diagnoses 
that are not 
well 
distinguishe
d in claims 
databases. 
 
Acute Renal 
Disease 
580.0,  580.4, 580.8, 580.9, 581.0, 581.1, 581.2, 581.2, 581.3, 581.8, 
581.9, 584.6, 584.7, 584.8, 584.9 
 
Chronic Renal 
Insufficiency 
582.x, 583.x, 585.x, 586.x, 587.x  
Diabetic 
Nephropathy 
250.4, 250.40, 250.41, 
250.42, 250.43 
 
Predictors Definition* Comments 
Hypertensive 
Nephropathy 
403.xx, 404.xx  
Miscellaneous 
Renal 
Insufficiency 
274.10, 440.1, 442.1, 453.3, 
581.xx, 593.xx, 753.0, 
753.3, 866.00 866.01, 
866.1 
 
ESRD (with and 
without dialysis) 
DIALYSIS 
ICD-9 procedure: 
39.95 hemodialysis 
54.98 peritoneal dialysis 
38.95 Venous catheterization for renal dialysis 
39.27 Arteriovenostomy for renal dialysis 
39.42 Revision of arteriovenous shunt for renal dialysis 
39.43 Removal of arteriovenous shunt for renal dialysis 
 
ICD-9 diagnoses: 
V45.1 renal dialysis status 
V56.0 extracorporeal dialysis 
V56.8 peritoneal dialysis 
 
CPT4: 
90935      HEMODIALYSIS PROC W/SINGLE PHYSICIAN EVALUATION 
90937      HEMODIALYSIS, REPEATED EVAL, W/WO REVISION DIALYSIS 
PRESCRIPTION 
90940      HEMODIALYSIS ACCESS FLOW STUDY, BY INDICATOR 
DILUTION METHOD, HOOK UP;  MEASUREMENT & 
DISCONNECTION 
90945      DIALYSIS, OTHER THAN HEMODIALYSIS, SINGLE PHYSICIAN 
EVAL 
90947      DIALYSIS PROCEDURE, OTHER THAN HEMODIALYSIS, 
REPEATED PHYSICIAN EVAL 
90989      DIALYSIS TRAINING, PATIENT, W/HELPER WHERE 
APPLICABLE, ANY MODE, COMPLETED COURSE 
 
Predictors Definition* Comments 
90993      DIALYSIS TRAINING, PATIENT, W/HELPER WHERE 
APPLICABLE, ANY MODE, COURSE INCOMPLETE, PER SESSION 
99512      HOME VISIT, HEMODIALYSIS 
99559      HOME INFUSION, PERITONEAL DIALYSIS, PER VISIT 
 
OR 
RENAL TRANSPLANT 
V42.0    Kidney transplant 
55.6x     Kidney transplant 
996.81  Complication of transplanted kidney 
 
CPT4: 
50360       RENAL ALLOTRANSPLANTATION, IMPLANTATION, GRAFT; 
W/O DONOR & RECIPIENT NEPHRECTOMY 
50365      RENAL ALLOTRANSPLANTATION, IMPLANTATION, GRAFT; 
W/RECIPIENT NEPHRECTOMY 
50380      RENAL AUTOTRANSPLANTATION, REIMPLANTATION, KIDNEY 
 
OR 
RENAL ICD9-defined ESRD 
585.5 ESKD with no mention of dialysis 
585.6 ESKD on dialysis 
 
COPD 491.xx, 492.xx, or 496.xx  
Asthma 493.xx   
Pneumonia 480.xx – 486.xx, 487.0x, 507.xx  
Alcohol abuse 
Alcohol abuse ICD-9 codes:  
94.61 – 94.63 – alcohol rehabilitation and detoxification 
94.67-94.69 – combined alcohol/drug rehabilitaion and 
detoxification 
303.0x – 303.9x – alcoholism 
 
Predictors Definition* Comments 
291.xx – alcohol-induced mental disorders 
357.5x – alcoholic polyneuropathy 
425.5x – alcoholic cardiomyopathy 
571.1x – acute alcoholic hepatitis 
571.2x – alcoholic cirrhosis of liver 
571.3x – alcoholic liver damage, unspecified 
305.0x  -alcohol abuse 
Drug abuse or 
dependence 
292.xx, 304.xx, 305.2x-305.9x  
 
Epilepsy or 
convulsions 
345.xx, 780.3x 
 
Cancer 
140.x-195.x, 196.x-198.x, 199.x, 200.x-208.x, 230.x-234.x, 235.x-
238.x, 239.x, excluding non-melanoma skin cancer ( = 173.xx), 
v10.xx  
 
Albumin level 
albumin <2.5, 2.5-3.49, ≥3.5 g/dL, vs missing indicator   
Serum creatinine As continuous variable and as a categorical variable (creatinine ≤1, 
1.01-1.99 and ≥2 mg/dL vs missing indicator  
 
Estimated 
glomerular 
filtration rate 
(eGFR) 
calculated by serum creatinine by CKD-EPI EQUATION 
(http://nephron.com/epi_equation) in and classified as (GFR≥60, 45 
to <60, 30 to <45, 15 to  <30, ESRD if GFR<15 or classified as ESRD 
based on the criteria above.  
 
aspartate 
aminotransferas
e (AST) level 
≤60, >60 to 100, >100 IU/L vs missing indicator 
 
Serum Alkaline 
phosphatase 
Serum Alkaline phosphatase level > 150, ≤ 150 U/L vs missing 
indicator  
 
Serum Sodium 
Serum Sodium level < 130, ≥130 mEq vs missing indicator  
BMI as a categorical variable (BMI≥ 40, 35-39.9, 30-34.9, 18.5-24.9, 
<18.5 vs missing indicator) 
 
Underweight 
Weight <50 vs ≥50 kg vs missing indicator  
Dementia 290.xx, 294.xx, 330.xx, 331.xx  
Depression 
293.83, 296.2x. 296.3x, 298.0x, 300.4x, 309.0x, 309.1x, 309.28, 
311.xx 
 
Bipolar disorder 296.0x, 296.1x, 296.4x, 296.5x, 296.6x, 296.7x, 296.8x, 296.99  
Predictors Definition* Comments 
Psychotic 
disorders 
290.8x, 290.9x, 295.xx, 297.xx, 298.xx, 299.xx, 780.1x   
 
*all the codes are assessed in the baseline period: 180 days prior to the index date 
 
Medication use 
predictors 
Generic drug names 
Antihypertensives Any of the following classes of antihypertensives 
ACE-Inhibitors 
Benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, 
quinapril, ramipril, trandolapril  
ARBs 
Azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, 
telmisartan, valsartan  
Beta-blockers 
Acebutolol, atenolol, betaxolol, bisoprolol, carteolol, carvedilol, esmolol, 
labetalol, metoprolol tartrate, metoprolol succinate, nadolol, nebivolol, 
penbutolol, pindolol, propranolol, sotalol, timolol 
Oral anticoagulants VKA, dabigatran, rivaroxaban, apixaban 
Antiplatelets 
Aspirin, lopidogrel, prasugrel, ticlopidine, aspirin–dipyridamole, aspirin, 
dipyridamole alone, cilostazol, ticagrelor 
Antidiabetics 
Insulin or acarbose, acetahexamide, albiglutide, alogliptin, canagliflozin, 
chlorpropamide, dapagliflozin, exenatide, glimepiride, glipizide, glyburide, 
linagliptin, liraglutide, metformin, miglitol, nateglinide, pioglitazone, 
pramlintide, repaglinide, rosiglitazone, saxagliptin, sitagliptin, tolazamide, 
tolbutamide, troglitazone 
Statins 
Atorvastatin, Fluvastatin, Lovastatin, Pitavastatin, Pravastatin , Rosuvastatin, 
Simvastatin 
Oral corticosteroids 
Cortisone, hydrocortisone, prednisone, prednisolone, methylprednisolone, 
triamcinolone, dexamethasone, 
bethamethasone 
Nonselective 
nonsteroidal anti-
inflammatory drugs 
Diclofenac, etodolac, flurbiprofen, ketorolac, ibuprofen, indomethacin, 
meloxicam, naproxen, piroxicam, sulindac, Ketoprofen, Oxaprozin, 
Nabumetone, Mefanamic acid, Meclofenamate, Fenoprofen, Diflunisal, 
Tolmetin 
Selective COX-2 
inhibitors 
Celecoxib, rofecoxib, valdecoxib 
Opioids  
Codeine, fentanyl, hydrocodone, hydromorphone, meperidine, morphine, 
oxycodone, propoxyphene, oxymorphone, tramadol 
Antibiotics 
daptomycin, gemifloxacin, telavancin, ceftaroline, fidaxomicin,amoxicillin, 
ampicillin, bacampicillin, carbenicillin, cloxacillin, dicloxacillin, flucloxacillin, 
mezlocillin, nafcillin, oxacillin, penicillin g, penicillin v, piperacillin, pivampicillin, 
pivmecillinam, ticarcillin, cefacetrile, cephacetrile, cefadroxil, cefadroxyl, 
cefalexin, cephalexin, cefaloglycin, cephaloglycin, cefalonium, cephalonium, 
cefaloridine,cephaloradine, cefalotin, cephalothin, cefapirin, cephapirin, 
cefatrizine, cefazaflur, cefazedone, cefazolin, cephazolin, cefradine, cephradine, 
cefroxadine, ceftezole, cefaclor, cefamandole, cefmetazole, cefonicid, cefotetan, 
cefoxitin,cefprozil, cefproxil, cefuroxime, cefuzonam, cefcapene, cefdaloxime, 
cefdinir, cefditoren, cefetamet, cefixime, cefmenoxime, cefodizime, cefotaxime, 
cefpimizole, cefpodoxime, cefteram, ceftibuten, ceftiofur, ceftiolene, 
ceftizoxime, ceftriaxone, cefoperazone, ceftazidime, cefclidine, cefepime, 
cefluprenam, cefoselis, cefozopran, cefpirome, cefquinome, ceftobiprole, 
ceftaroline, ertapenem, aztreonam, cefoxazole, ceftazidime, avibactam, 
imipenem, imipenem, cilastatin, doripenem, meropenem, cefaclomezine, 
cefaloram, cefaparole, cefcanel, cefedrolor, cefempidone, cefetrizole, cefivitril, 
cefmatilen, cefmepidium, cefovecin,   cefsumide, cefuracetime, ceftioxide, 
erythromycin, clarithromycin, dirithromycin, roxithromycin, telithromycin, 
clindamycin, lincomycin, pristinamycin, quinupristin, medication,'dalfopristin, 
amikacin, gentamicin, kanamycin, neomycin, netilmicin, paromomycin, 
streptomycin, tobramycin, flumequine, nalidixic acid, oxolinic acid, piromidic 
acid, pipemidic acid, rosoxacin, ciprofloxacin, enoxacin, lomefloxacin, 
nadifloxacin, norfloxacin, ofloxacin, pefloxacin, rufloxacin, balofloxacin, 
gatifloxacin, grepafloxacin, levofloxacin, vancomycin, teicoplanin, telavancin, 
linezolid, cycloserine 2, rifampin, rifabutin, rifapentine, rifalazil, bacitracin, 
polymyxin b, viomycin,     oxifloxacin, pazufloxacin, sparfloxacin, temafloxacin, 
tosufloxacin, besifloxacin, clinafloxacin, gemifloxacin, sitafloxacin, trovafloxacin, 
prulifloxacin, sulfamethizole, sulfamethoxazole, sulfisoxazole, trimethoprim-
sulfamethoxazole, demeclocycline, doxycycline, minocycline, oxytetracycline, 
tetracycline, tigecycline, chloramphenicol, metronidazole, tinidazole, 
nitrofurantoin 
ACEI= angiotensin converting enzyme inhibitors, ARB= angiotensin II receptor blockers 
 
 
  
Table S4. Sensitivity analysis: Similar performance with composite vs. specific outcomes 
 SAMe-TT2R2 Score New geriatric score  
 AUC in the 
training set 
AUC in the validation 
set (AF+VTE) 
AUC in the 
training set 
AUC in the validation 
set (AF+VTE) 
Composite 
outcomes* 
0.53 0.59 0.65 0.72 
Thrombotic 
outcomes** 
0.56 0.60 0.65 0.72 
Bleeding 
outcomes*** 
0.49 0.57 0.64 0.71 
AF= atrial fibrillation, VTE=venous thromboembolism, AUC= Area Under Receiver Operating 
Characteristic curve 
*Including the thrombotic outcomes and bleeding outcomes listed below 
** Including ischemic stroke, arterial thromboembolism, deep vein thrombosis, pulmonary embolism 
per definitions in Table S2 
*** Including intracranial and extracranial major bleeding per definitions in Table S2 
 
  
Table S5. Hosmer-Lemeshow Goodness-of-fit table of geriatric TTR model in the validation set 
Deciles by 
predicted 
TTR 
N of patients TTR>70% TTR≤70% 
Observed N of 
events 
Expected N of 
events 
Observed N of 
events 
Expected N of 
events 
1 103 10 10.06 93 92.94 
2 103 13 15.18 90 87.82 
3 103 20 18.49 83 84.51 
4 103 24 21.74 79 81.26 
5 103 20 25.62 83 77.38 
6 103 33 29.58 70 73.42 
7 103 36 33.39 67 69.61 
8 103 38 38.35 65 64.65 
9 103 44 44.89 59 58.11 
10 106 55 55.69 51 50.31 
Hosmer and Lemeshow goodness-of-fit Test: Chi-squared=3.4, Degree of freedom=8, P value=0.91 
TTR =time in therapeutic range 
   
Table S6. Sensitivity analysis: Similar performance with different analysis strategies 
 Version of scores   AUC in the 
training set 
AUC in the validation 
set (AF+VTE) 
Original TTR>70% 0.71 0.68 
Clinical outcome 0.65 0.72 
Defining BAP as 365 days TTR>70% 0.72 0.67 
Clinical outcome 0.65 0.70 
Defining new initiation as no 
use in the 180 days prior to 
the index date 
TTR>70% 0.71 0.69 
Clinical outcome 0.66 0.72 
After Box-Cox transformation 
of TTR 
TTR>70% 0.71 0.68 
Clinical outcome 0.65 0.72 
After excluding patients with 
zero TTRs 
TTR>70% 0.70 0.66 
Clinical outcome 0.66 0.72 
AF= atrial fibrillation, VTE=venous thromboembolism, BAP=baseline assessment period, AUC= 
Area Under Receiver Operating Characteristic curve  
 
  
 Table S7. New geriatric prediction model for anticoagulation control quality* based on only variables 
available in an insurance claims database  
Predictors Coefficients** s.e. Predictors Coefficients** s.e. 
Intercept 0.655 0.021 # of regular medications 5-9 -0.037 0.014 
AF vs. VTE 0.002 0.013 # of regular medications ≥10 -0.050 0.020 
Sex female vs male -0.014 0.014 # of regular medications <5 ref . 
Black race -0.052 0.037 Hospitalization days≥7 days: 
yes vs no 
-0.018 0.016 
Non-black non-
white races 
0.041 0.025 Use of BB 0.026 0.014 
White ref 
 
Use of ACEI 0.027 0.013 
CHF -0.022 0.016 Use of ARB 0.022 0.017 
DM -0.011 0.014 Use of metolazone -0.115 0.092 
Epilepsy -0.020 0.029 Use of opioids -0.022 0.016 
Cancer -0.027 0.012 Use of statins -0.033 0.015 
CR_Dementia -0.008 0.019 Use of acetaminophen -0.006 0.016 
Renal dysfunction -0.060 0.014 Use of antibiotics -0.022 0.013 
Prior bleeding¥ -0.029 0.015 Use of oral steroids -0.018 0.017 
COPD or asthma -0.004 0.014 Influenza vaccine 0.021 0.013 
Pneumonia -0.027 0.016 PSA Test 0.043 0.018 
Prior stroke -0.016 0.015 Colonoscopy -0.020 0.023 
Drug abuse -0.057 0.058 Mammography 0.068 0.023 
Chronic liver 
disease 
-0.039 0.022 Pap smear -0.073 0.039 
Psychosis -0.019 0.026 Falls -0.011 0.022 
Peripheral 
vascular disease 
-0.034 0.017 Fractures -0.029 0.021 
Hyperlipidemia 0.032 0.015 Parkinson's disease 0.093 0.045 
* Quantified by International Normalized Ratio (INR) time in therapeutic range (TTR).  
** unstandardized coefficients based on a Lasso regression model including all the variables listed in this 
table. 
***Including all the major upper and lower gastrointestinal and other extracranial bleeding events. 
AF= atrial fibrillation, VTE=venous thromboembolism, CHF= congestive heart failure, DM= diabetes 
mellitus, COPD=chronic obstructive pulmonary disease, BB=beta-blocker, ACEI= angiotensin converting 
enzyme inhibitors, ARB= Angiotensin II receptor blockers, PSA= Prostate-specific antigen 
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